Using oligodendrocyte-derived vesicles to treat autoimmune diseases of the central nervous system
Oligodendrocyte extracellular vesicles: a novel therapy for CNS autoimmunity
This study is exploring a new treatment for multiple sclerosis that uses tiny particles from brain cells to help calm the immune system without causing unwanted side effects, aiming to provide a safer and more effective option for people living with MS.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11042165 on NIH RePORTER |
What this research studies
This research investigates a new therapy for central nervous system (CNS) autoimmune diseases, particularly multiple sclerosis (MS), by utilizing extracellular vesicles derived from oligodendrocytes. The approach aims to specifically target harmful immune responses without affecting the overall immune system, potentially reducing side effects associated with current treatments. By identifying and delivering myelin antigens in a non-inflammatory manner, the study seeks to re-establish tolerance to these self-antigens. This could lead to a more effective and safer treatment option for patients suffering from MS and similar conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple sclerosis or other CNS autoimmune disorders.
Not a fit: Patients with non-autoimmune neurological conditions or those who do not have a diagnosis of CNS autoimmunity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a targeted therapy that minimizes side effects and improves treatment outcomes for patients with CNS autoimmune diseases.
How similar studies have performed: Previous research has shown promise in using antigen-specific therapies for autoimmune conditions, but this approach using oligodendrocyte-derived vesicles is relatively novel.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Rostami, A.m. — Thomas Jefferson University
- Study coordinator: Rostami, A.m.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.